Big Board Alerts

2024 Agenda Revealed: 4th Wet AMD & Diabetic Eye Disease Drug Development Summit

With the recent FDA-approvals of Bayer’s Eylea HD 8mg as a durable long-term treatment for Wet AMD and Genentech’s Vabysmo for Retinal Vein Occlusion (RVO), now is the time to unite with fellow retinal vascular experts to harness novel ophthalmic innovations to accelerate long-lasting and efficacious drug development targeting neovascularization in the eye.

To aid this comes the return of the 4th Wet AMD & Diabetic Eye Disease Drug Development Summit to Boston, with exciting new data, fresh perspectives, and your shining opportunity to unite with fellow experts working on retinal vascular drug development.

The 18+ industry expert speakers include:

Jayashree Sahni, Senior Global Program Clinical Head,Novartis
Sergio Leal, Global Clinical Leader, Bayer
Daniela Ferrara, Principal Medical & Ophthalmology Director, Genentech
Pablo Velazquez-Martin,Senior Vice President, Clinical Research & Translational Medicine, Kodiak Sciences
Kerrie Brady, Chief Executive Officer, OcuTerra Therapeutics
Andrea Giani, Global Head of Medicine Retinal Health, Boehringer Ingelheim

Join 70+ industry-based retinal vascular experts from the likes of Bayer, Boehringer Ingelheim, Genentech, Novartis and OcuTerra, at the definitive industry-focused forum designed to allow preclinical and clinical R&D scientists to harness novel ophthalmic innovations to accelerate long-lasting and efficacious drug development targeting neovascularization in the eye.

For additional information on the program, tickets and more, visit: wet-amd-drug-development.com

The post 2024 Agenda Revealed: 4th Wet AMD & Diabetic Eye Disease Drug Development Summit appeared first on Pharma Journalist.

 

Latest Articles

DON’T MISS THE OPPORTUNITY TO JOIN OUR MARKET SUMMARY REPORT FOR A LIMITED TIME

By submitting this form on our website, you agree that we may collect and use your personal information for marketing, and for other purposes as set forth in our privacy policy, which we encourage you to review.